Last reviewed · How we verify
NCT04688749: DermaSense
Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage
trial testing Electrical Impedence Spectroscopy DermaSense in Melanoma (Skin) in 50 participants. Terminated before completion.
31 December 2022
Quick facts
| Lead sponsor | Aristotle University Of Thessaloniki |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 17 July 2019 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across Greece |
Drugs / interventions tested
- Electrical Impedence Spectroscopy DermaSense
Conditions studied
- Melanoma (Skin) — all drugs for Melanoma (Skin) →
- Basal Cell Carcinoma — all drugs for Basal Cell Carcinoma →
- Squamous Cell Carcinoma — all drugs for Squamous Cell Carcinoma →
- Dysplastic Nevus Syndrome — all drugs for Dysplastic Nevus Syndrome →
Sponsor
Aristotle University Of Thessaloniki
Who can join
Adults 8 to 90, any sex, with Melanoma (Skin) or Basal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this clinical study is to evaluate if the DermaSense prototype EIS scanner can provide medical decision support which can complement dermoscopy-based identification of the disease at time of biopsy decision.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04688749
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Melanoma (Skin)
Currently open trials in the same condition.
- NCT06643286 — Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma · NA · recruiting
- NCT06298734 — High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial · NA · recruiting
- NCT05704647 — Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases · Phase 2 · recruiting
- NCT05492682 — START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer · Phase 1 · active not recruiting
- NCT05649683 — Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors · NA · recruiting
Other Aristotle University Of Thessaloniki trials
Trials by the same sponsor.
- NCT07382479 — NeoAdjuvant ChemoTherapy With KELIM Guided Interval vs. Delayed Interval Debulking Surgery · NA · not yet recruiting
- NCT07379905 — MODUCARE Versus Wait-and-See Approach for Histologically Proven Low-grade Cervical Intraepithelial Neoplasia (CIN1) · NA · not yet recruiting
- NCT07335016 — The Role of Follicular Flushing at Oocyte Retrieval · NA · not yet recruiting
- NCT07297121 — Validation of the Montreal Cognitive Assessment (MoCA) Version 8.x and MoCA-MIS in Greece. · not yet recruiting
- NCT07210164 — Pre-habilitation Within ERAS Protocol for Gynecologic Oncology Surgery: The Pre_ERAS Study · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04688749 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aristotle University Of Thessaloniki
- Last refreshed: 25 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04688749.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing